Abstract Word Count: 248 Word Count: 3696 References: 21 AT A GLANCE COMMENTARY: Scientific Knowledge on the Subject: Recurrent respiratory infections in individuals with cystic fibrosis may result in permanent loss of lung function, thus increasing morbidity and mortality. The optimal approach to treating these infections remains unclear. What This Study Adds to the Field: This study demonstrates no difference in short-and long-term lung function improvement, regardless of whether therapy is administered in inpatient or outpatient settings. Lung function measurements obtained during therapy suggest that longer courses of antibiotics (14-21 days) may not confer additional improvement in lung function over shorter courses (8-10 days).
Introduction
In 2008 the median predicted age of survival in the U.S. for people with cystic fibrosis (CF) was 37.4 years with the primary cause of morbidity and mortality being progressive obstructive lung disease. 1 Progression of lung disease may be hastened by recurrent severe respiratory infections termed respiratory exacerbations, which are characterized by a decline in spirometry, dyspnea, hypoxia, increased cough or sputum production, and/or weight loss.
Traditional management includes aggressive airway clearance and antibiotics, the latter frequently administered intravenously. Despite effective symptomatic therapy, patients may not completely recover their baseline lung function. Thus, it is crucial to determine the most effective therapy for CF respiratory exacerbations. Unfortunately, due to the difficulty of performing randomized controlled trials, existing evidence is insufficient for many treatment issues. 2;3 Two of these key issues, namely the best site for delivery of intravenous antibiotic course (i.e. administration at home or in the hospital) and the optimal duration of therapy could be studied by examining outcomes in a large registry.
Outpatient intravenous therapy has gained widespread acceptance because of its advantages over hospitalization including: fewer absences from school or work and less disruption of family life, [4] [5] [6] [7] decreased costs per treatment course, [4] [5] [6] [7] [8] and high patient satisfaction. [4] [5] [6] On the other hand, long-term costs may not be reduced in the outpatient setting due to the need for longer and more frequent courses of antibiotics, 9 and quality of life may not be better across all domains. 7;10 Additionally, several studies have documented no difference between inpatient and outpatient therapy in terms of compliance with antibiotic therapy, 5 or improvement in forced expiratory volume in 1 second (FEV 1 ). 4-7;10-13 Conversely, other studies have shown a significantly greater improvement in FEV 1 after inpatient treatment compared to outpatient treatment. 9;14-17 It is important to recognize that most studies have consisted of fewer than 100 patients in a few clinical sites, which may result in limited power and clinicspecific biases. In addition, most studies have not followed patients for prolonged periods to determine if the choice of venue alters long-term lung function.
An equally pressing question is the optimal duration of therapy. 3 Although intravenous antibiotics are frequently prescribed for several weeks for CF respiratory exacerbations, treatment data from other lower respiratory tract infections, such as ventilator-associated pneumonia, suggests that shorter courses (8 days) may be as efficacious as longer courses (15 days) . 18 This begs the question of whether shorter duration of therapy would provide the same clinical benefits as longer courses for the treatment of CF respiratory exacerbations, while reducing disruption of family life, costs, drug toxicity, allergic reactions, and/or bacterial resistance.
This study uses data from the U.S. Cystic Fibrosis Twin-Sibling Study for a large multicenter analysis of these questions. We hypothesize that inpatient therapy results in better outcomes (i.e., immediate improvement in lung function, arrest in long-term lung function decline, and longer intervals between courses of intravenous therapy) than outpatient therapy.
We also seek to determine whether shorter duration of therapy leads to similar outcomes as longer duration, as measured by improvement in FEV 1 .
Methods
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Participants: 1535 individuals in 755 families were recruited through the U.S. Cystic
Fibrosis Twin-Sibling Study under the oversight of the Johns Hopkins University IRB. All subjects met diagnostic criteria for CF. 19 All subjects used in the analyses attended CF Centers accredited by the U.S. Cystic Fibrosis Foundation. Informed written consent was obtained from all subjects and/or guardians. Pulmonary function and respiratory culture data collected by the Twin-Sibling
Study were supplemented using the Cystic Fibrosis Foundation (CFF) Patient Registry. Therapy starting and ending dates and location of therapy were obtained from the CFF Patient Registry.
Analysis was limited to courses of intravenous antibiotics ≤42 days in duration clinically number of pulmonary function tests averaged for each lung function measure were 7.1 ± 5.0, 1.3 ± 0.6, 1.3 ± 0.6, and 6.7 ± 5.1 for Baseline FEV 1 , Pre-therapy FEV 1 , Post-therapy FEV 1 , and New Baseline FEV 1 , respectively. Three indices were derived to describe changes in lung function. The primary outcome, Baseline Change, was intended to provide a measure of longterm change following a course of therapy, thus an indicator of long-term prognosis. Immediate
Recovery was intended to provide a measure of short-term recovery of FEV 1 with treatment. 
Results
Demographics: Courses of antibiotic therapy within the dataset were divided into three groups, Home, Hospital, and Combination as described above. Individual subjects may have received treatment in different venues on separate occasions. Groups differed significantly by gender, age, and duration of therapy (Table 1) . Subjects receiving therapy entirely in the home setting were more likely to be female than in other groups. This gender phenomenon has been reported previously. 13;14 When looking at the data by exacerbation, subjects who received therapy entirely in the hospital were younger than other groups and those receiving therapy entirely in the home were older than other groups. Those receiving therapy entirely in the hospital were treated for fewer days compared to other groups. Average lung function before and after therapy were not different between the groups treated entirely in the hospital or the home.
Therapy for an exacerbation does not necessarily preserve long-term lung function:
Patients in all 3 groups experienced a decrease in FEV 1 just prior to treatment for an exacerbation, generally followed by recovery to the previous baseline immediately after treatment ( Figure 2 ). More importantly, the new baseline FEV 1 following an exacerbation was lower than the previous baseline prior to the exacerbation, regardless of venue (p<0.0001).
Hospital Therapy does not produce better outcomes than Home therapy: Using both ttests and adjusted linear regression, no differences were found in long-term lung function between inpatient vs. outpatient therapy. Using the courses of therapy from Bias may arise in the previous analysis given that an individual subject may not be represented in both groups. Thus, courses of therapy from 32 subjects who had data from separate treatment courses in both entirely in the hospital and entirely in the home are compared in Table 2 ; the most recent hospital and home courses of therapy for each subject were used for this analysis. Courses of therapy were temporally separated by a mean (±SD) of Examining the long-term outcome (Baseline Change), the variable for venue drops out of the final regression model (Supplemental Table 3 ), but the final model predicts that subjects with a greater decline in lung function prior to initiation of therapy experience a worse long-term decline following that course of therapy (Sick Change p<0.001). This holds true even if the final model is adjusted for Immediate Recovery (Supplemental Table 4 : Sick Decline p<0.001). This implies that patients with drastic drops in lung function should be monitored more closely following treatment, for even with recovery of lung function, they remain at higher risk for greater long-term decline.
Performing a separate regression analysis on short-term outcome (Immediate Recovery), the variable for venue also failed to reach significance in the final regression model (Supplemental Table 5 ), suggesting that location may be less important in both short-term and long-term outcomes than the other factors included in the models. Finally, subjects with a greater initial decline in lung function also have a greater improvement in FEV 1 ; the coefficient of the final model suggests that on average subjects regain 72% of their lost lung function immediately after completing antibiotic therapy. Of note, shorter courses of antibiotics were associated both better short and long-term outcomes. Table 6 ). The significant predictors in the final model for worse long-term lung function decline included greater initial drops in lung function with illness, the presence of P. aeruginosa, and longer duration of therapy.
However, a greater percentage of time spent in the hospital for treatment of an exacerbation was associated with a shorter interval until next exacerbation requiring intravenous antibiotics, even after correcting for baseline lung function and total length of therapy using regression exacerbations. Furthermore, clinicians should not be necessarily reassured with complete recovery of lung function in patients who had a greater drop with illness. These patients remain at a higher risk for long-term decline. These results demonstrate that determining an optimal approach to the treatment of pulmonary exacerbations is of vital importance to the CF community.
Currently, there is little evidence to direct physicians' therapies of exacerbations. Prior studies have provided conflicting results as to the efficacy of intravenous antibiotic therapy administered at home compared to that administered in the hospital. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The only prospective randomized study of the venue of antibiotic administration for respiratory exacerbations in CF patients published to date found that there was no difference in lung function by therapy venue. 7 Our multi-center study also did not observe any differences in short-term improvement in FEV 1 (Immediate Recovery) when therapy was performed at home compared to in the hospital setting.
We also did not observe any differences in long-term lung function decline (Baseline Change) either by examining the entire study population, separate home and hospital courses within the same individual, or adjusted linear regression, which includes correction for age and duration of therapy. In subjects whose antibiotic therapy was divided between the hospital and A key design difference between our study and the prior studies is that in both of these studies subjects categorized as "Home" may have received up to 40% of their therapy in the hospital, and vice versa for those categorized as "Hospital." Also, both of these studies were conducted in Europe where practice patterns in the home and hospital may vary from the U.S. leading to the differing observed results.
The optimal duration of therapy for a pulmonary exacerbation is also unknown. However, this study was limited to 17 subjects with more severe lung disease than our population (Mean admission FEV 1 : 26 ± 9 %). Prospective trials to assess improvement in FEV 1 and other clinical parameters to determine optimal duration of intravenous antibiotics as well as risk factors for slower improvement that may require longer courses of antibiotics are needed.
Limitations to this study include the absence of an objective pre-determined definition for a respiratory exacerbation. This study is subject to the treating clinician's judgment for what constitutes a "pulmonary exacerbation" requiring intravenous antibiotics, but this range of clinical criteria may better reflect current practices. Additionally, the length of therapy is also based on the clinician's judgment and is likely influenced by factors other than FEV 1 , such as dyspnea, fever, and/or continued cough, which were not assessed in this study. We also were unable to assess other factors in the decision as where to treat, including, but not limited to, social support, compliance, payer restrictions, other co-morbidities, and/or families' prior experience. Also, the analyses' requirements of complete pulmonary function data prior to and after therapy may exclude subjects who are: non-compliant with recommended follow-up, in better health and not requiring frequent pulmonary function testing, and under the age of 6 years old who cannot reliably perform pulmonary function testing. Additionally, no difference between home and hospital therapy may have been observed due to possible biases inherent in using averages of lung function, rather than the highest lung function in a given time period, which may bias against hospital-treated patients with frequent exacerbations who have brief episodes of decreased lung function, and in using data from a family-based study as the experience for siblings with CF may be different than that of a single child with CF. Subjects who participate in the Twin-Sibling Study may be more motivated than the general CF population, and thus may have increased compliance with antibiotics and chest physiotherapy when treated at home. These subjects are also members of families where more than one sibling has CF, thus these families may be more adept with home care. Also, our study was biased towards older subjects who had more data available for analyses, and thus our findings may not be as Table 1 data): This figure provides the mean values for each measure of lung function before and after a respiratory exacerbation by venue of treatment. As can be seen, all groups experience a substantial decline in lung function with an exacerbation, followed by recovery in some cases back to the original baseline, but long-term lung function is decreased compared to the original baseline lung function. 95% confidence intervals for all lung function measures can be found in Supplemental Table 2 . Supplemental Figure 
